Diffuse Large B-Cell Lymphoma Clinical Trials

A listing of 34 Diffuse Large B-Cell Lymphoma clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Diffuse Large B-Cell Lymphoma

1 - 12 of 34

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 34 active clinical trials seeking participants for Diffuse Large B-Cell Lymphoma research studies. The states with the highest number of trials for Diffuse Large B-Cell Lymphoma participants are California, New York, Ohio and Texas.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Offer

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

NCT05139017

Recruiting

The purpose of this Phase 2/3, randomized, multisite, open-label, dose confirmation, and expansion study is to evaluate the safety, and efficacy of zilovertamab vedotin (ZV) in combination with standard of care options for the treatment of rrDLBCL. This study will be divided into 2 parts: Dose Confirmation (Part 1) and Efficacy Expansion (Part 2) and will enroll participants who are at least 18 years of age with rrDLBCL. The hypotheses are: ZV in combination with rituximab, gemcitabine, and oxal... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/26/2025

Locations: Bass Medical Group ( Site 0166), Walnut Creek, California +103 locations

Bass Medical Group ( Site 0166), Walnut Creek, California

Innovative Clinical Research Institute ( Site 0122), Whittier, California

Boca Raton Regional Hospital- Lynn Cancer Institute ( Site 0163), Boca Raton, Florida

Saint Elizabeth Medical Center Edgewood ( Site 0165), Edgewood, Kentucky

University of Kentucky Chandler Medical Center ( Site 0158), Lexington, Kentucky

Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0133), Louisville, Kentucky

Louisiana State University Health Sciences Center New Orleans ( Site 0134), New Orleans, Louisiana

University of Maryland ( Site 0123), Baltimore, Maryland

Dana-Farber Cancer Institute-Lymphoma ( Site 0111), Boston, Massachusetts

University of Massachusetts Medical School ( Site 0119), Worcester, Massachusetts

St. Vincent Frontier Cancer Center-Research ( Site 0108), Billings, Montana

Atlantic Health System ( Site 0116), Morristown, New Jersey

New York Medical College ( Site 0113), Valhalla, New York

Vanderbilt University Medical Center-Vanderbilt-Ingram Cancer Center ( Site 0156), Nashville, Tennessee

Hospital Italiano de Buenos Aires ( Site 2203), Ciudad Autonoma de Buenos Aires, Buenos Aires

Instituto de Investigaciones Clínicas Mar del Plata ( Site 2205), Mar del Plata., Buenos Aires

Hospital Aleman ( Site 2200), Buenos Aites, Caba

Instituto Alexander Fleming ( Site 2201), Caba, Not set

Hospital Privado Universitario de Córdoba ( Site 2202), Cordoba, Not set

Townsville University Hospital ( Site 1800), Douglas, Queensland

Grampians Health ( Site 1802), Ballarat, Victoria

Royal Perth Hospital-Haematology ( Site 1801), Perth, Western Australia

Hospital Erasto Gaertner ( Site 2302), Curitiba, Parana

Liga Norte Riograndense Contra o Câncer ( Site 2305), Natal, Rio Grande Do Norte

Hospital Paulistano ( Site 2300), Sao Paulo, Not set

Pesquisa Clínica do Serviço de Hematologia do Hospital das Clínicas da FMUSP ( Site 2306), Sao Paulo, Not set

Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0200), Toronto, Ontario

Biocenter ( Site 2401), Concepcion., Biobio

IC La Serena Research ( Site 2405), La Serena, Coquimbo

Oncocentro Valdivia ( Site 2407), Valdivia., Los Rios

FALP-UIDO ( Site 2400), Santiago., Region M. De Santiago

Clínica Inmunocel ( Site 2404), Santiago, Region M. De Santiago

Clínica RedSalud Vitacura ( Site 2409), Santiago, Region M. De Santiago

Bradfordhill ( Site 2403), Santiago, Region M. De Santiago

Beijing Cancer hospital ( Site 3000), Beijing, Beijing

Chongqing University Cancer Hospital-Medical Oncology ( Site 3025), Chongqing, Chongqing

Chongqing University Three Gorges Hospital ( Site 3026), Chongqing, Chongqing

Sun Yat-sen University Cancer Center-Internal Medicine ( Site 3001), Guangzhou, Guangdong

Zhujiang Hospital ( Site 3002), Guangzhou, Guangdong

The First Affiliated Hospital of Henan University of Science &Technology ( Site 3029), Luoyang, Henan

Henan Cancer Hospital-hematology department ( Site 3013), Zhengzhou, Henan

Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 3017), Wuhan, Hubei

The First Affiliated Hospital of Nanchang University ( Site 3004), Nanchang, Jiangxi

Jiangxi Provincial Cancer Hospital ( Site 3005), Nanchang, Jiangxi

The First Hospital of Jilin University-Hematology ( Site 3012), Changchun, Jilin

Fudan University Shanghai Cancer Center ( Site 3009), Shanghai, Shanghai

West China Hospital of Sichuan University-Head and Neck Oncology ( Site 3016), Cheng Du, Sichuan

Sichuan Cancer hospital-Oncology ( Site 3021), Chengdu, Sichuan

Zhejiang Cancer Hospital ( Site 3014), Hangzhou, Zhejiang

The First Affiliated Hospital Zhejiang University School of Medicine ( Site 3027), Hangzhou, Zhejiang

Hospital Pablo Tobon Uribe ( Site 0804), Medellin, Antioquia

Instituto Médico de Alta Tecnologia S.A.S ( Site 0803), Monteria, Cordoba

FUNDACION CTIC CENTRO DE TRATAMIENTO E INVESTIGACION SOBRE CANCER LUIS CARLOS SARMIENTO ANGULO ( Site 0801), Bogota, Distrito Capital De Bogota

Oncologos del Occidente ( Site 0800), Pereira., Risaralda

Fundacion Valle del Lili ( Site 0802), Cali, Valle Del Cauca

Hospital Metropolitano - Sede Lindora ( Site 2500), Santa Ana, San Jose

CIMCA ( Site 2501), San Jose, Not set

centre hospitalier lyon sud-Service Hématologie ( Site 0702), Pierre-Bénite, Rhone

Pitie Salpetriere University Hospital-Clinical haematology ( Site 0700), Paris, Not set

University Hospital of Alexandroupolis ( Site 0903), Alexandroupolis, Anatoliki Makedonia Kai Thraki

Evangelismos General Hospital of Athens ( Site 0900), Athens, Attiki

Regional General Hospital of Athens "Laiko" ( Site 0901), Athens, Attiki

MEDI-K ( Site 2602), Guatemala, Not set

Private Practice- Dr. Rixci Augusto Lenin Ramírez ( Site 2601), Guatemala, Not set

CELAN,S.A ( Site 2603), Guatemala, Not set

Queen Mary Hospital ( Site 3100), Hong Kong, Not set

Princess Margaret Hospital ( Site 3101), Hong Kong, Not set

Emek Medical Center-Hematology Unit ( Site 1102), Afula, Not set

Carmel Hospital ( Site 1103), Haifa, Not set

Hadassah Medical Center ( Site 1100), Jerusalem, Not set

Humanitas-U.O di Oncologia medica ed Ematologia ( Site 1203), Rozzano, Milano

IRCCS - AOU di Bologna-Istituto di Ematologia "L. e A. Seragnoli" ( Site 1200), Bologna, Not set

Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 1202), Napoli, Not set

Fondazione Policlinico Universitario Agostino Gemelli IRCCS -ISTITUTO DI EMATOLOGIA ( Site 1204), Roma, Not set

Seoul National University Hospital-Oncology ( Site 0302), Seoul, Not set

Samsung Medical Center ( Site 0300), Seoul, Not set

Aotearoa Clinical Trials ( Site 0501), Auckland, Not set

Clínicas AUNA Sede Chiclayo ( Site 2803), Chiclayo, Lambayeque

Clínica San Felipe ( Site 2805), Lima, Not set

Specjalistyczny Szpital im. Dr Alfreda Sokolowskiego w Walbrzychu ( Site 1305), Walbrzych, Dolnoslaskie

Uniwersytecki Szpital Kliniczny-Klinika Hematologii, Nowotworow Krwi i Transplantacji Szpiku ( Site 1301), Wroclaw, Dolnoslaskie

Centrum Onkologii Ziemi Lubelskiej-Oddzial Hematologii i Transplantacji Szpiku ( Site 1304), Lublin, Lubelskie

Pratia MCM Krakow ( Site 1303), Krakow, Malopolskie

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworów Układu Chłonnego ( Site 1300), Warszawa, Mazowieckie

Szpitale Pomorskie Sp. z o. o.-Hematology and Bone Marrow Transplantation Department ( Site 1302), Gdynia, Pomorskie

Wojewódzki Szpital Specjalistyczny im. J. Korczaka w Słupsku ( Site 1309), Słupsk, Pomorskie

Pratia Onkologia Katowice ( Site 1306), Katowice, Slaskie

Faculty of Medicine Siriraj Hospital-Division of Hematology, Department of Medicine ( Site 0400), Bangkok, Krung Thep Maha Nakhon

Chulalongkorn University ( Site 0402), Pathumwan, Krung Thep Maha Nakhon

Maharaj Nakorn Chiang Mai Hospital ( Site 0401), Chiang Mai, Not set

Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastırma Hastanesi ( Site 1912), Yenimahalle, Ankara

Ege University Medicine of Faculty ( Site 1902), Bornova, Izmir

Ankara University Hospital Cebeci-hematology ( Site 1901), Ankara, Not set

Mega Medipol-Hematology ( Site 1909), Istanbul, Not set

Dokuz Eylül Üniversitesi-Hematology ( Site 1905), Izmir, Not set

Ondokuz Mayıs Universitesi ( Site 1907), Samsun, Not set

MNPE ClinCenter of Oncology,Hematology,Transplantology and Palliative Care of CherkasyRegCouncil ( Site 2000), Cherkasy, Cherkaska Oblast

Communal non-profit enterprise "Regional clinical hospital of Ivano-Frankivsk Regional Council" ( Site 2004), Ivano-Frankivsk, Ivano-Frankivska Oblast

Institute of Blood Pathology and Transfusion Medicine AMS Ukraine ( Site 2002), Lviv, Lvivska Oblast

State non-profit enterprise National Cancer Institute ( Site 2001), Kyiv, Not set

National Research Center for Radiation Medicine of National Academy of Medical Sciences of Ukraine ( Site 2005), Kyiv, Not set

Public Non-Profit Enterprise Kyiv City Clinical Hospital #9 under the Executive Body of Kyiv City Co ( Site 2003), Kyiv, Not set

Aberdeen Royal Infirmary ( Site 2104), Aberdeen, Aberdeen City

University College London Hospital-Cancer Clinical Trials Unit ( Site 2100), London-Camden, London, City Of

Conditions: DLBCL, Diffuse Large B-Cell Lymphoma

Learn More ›

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

NCT03223610

Recruiting

Background: B-cell lymphoma is a cancer of white blood cells found in the lymph nodes. It affects the system that fights infections and disease. Researchers want to learn how certain drugs work together to treat B-cell lymphomas. The drugs are venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR). Objective: To study the safety of ViPOR for people with B-cell lymphoma. Eligibility: People ages 18 and older with B-cell lymphoma whose cancer has returned or not improved af... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/25/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Burkitt Lymphoma

Learn More ›

Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL

NCT05952024

Recruiting

The study will measure the safety, tolerability, and efficacy with acalabrutinib in combination with rituximab in treatment-naïve elderly and/or frail patients with diffuse large B-cell lymphoma (DLBCL), who are otherwise unsuitable for standard front line chemoimmunotherapy treatments.

Gender:

ALL

Ages:

Between 65 years and 99 years

Trial Updated:

06/25/2025

Locations: Research Site, La Jolla, California +51 locations

Research Site, La Jolla, California

Research Site, Orange, California

Research Site, Stamford, Connecticut

Research Site, Jacksonville, Florida

Research Site, Des Moines, Iowa

Research Site, Lexington, Kentucky

Research Site, Beltsville, Maryland

Research Site, Towson, Maryland

Research Site, Detroit, Michigan

Research Site, Sioux Falls, South Dakota

Research Site, Lubbock, Texas

Research Site, Olympia, Washington

Research Site, Tacoma, Washington

Research Site, Barretos, Not set

Research Site, Belo Horizonte, Not set

Research Site, Brasilia, Not set

Research Site, Campinas, Not set

Research Site, Curitiba, Not set

Research Site, Florianópolis, Not set

Research Site, Goiania, Not set

Research Site, Natal, Not set

Research Site, Porto Alegre, Not set

Research Site, Recife, Not set

Research Site, Ribeirão Preto, Not set

Research Site, Rio de Janeiro, Not set

Research Site, Sao Luis, Not set

Research Site, Sao Paulo, Not set

Research Site, Sorocaba, Not set

Research Site, São José do Rio Preto, Not set

Research Site, São Paulo, Not set

Research Site, Busan, Not set

Research Site, Daegu, Not set

Research Site, Gyeongsangnam-do, Not set

Research Site, Incheon, Not set

Research Site, Jeonju-si, Not set

Research Site, Seo-gu, Not set

Research Site, Seoul, Not set

Research Site, Suwon-si, Not set

Research Site, Ulsan, Not set

Research Site, San Juan, Not set

Conditions: Diffuse Large B-Cell Lymphoma

Learn More ›

A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.

NCT05896163

Recruiting

The purpose of this study is to learn about the effects of two study medicines (maplirpacept \[PF-07901801\] and glofitamab) when given together for the treatment of diffuse large B-cell lymphoma (DLBCL) that is relapsed or is refractory. Relapsed means has returned after last treatment. Refractory means that it has not responded to last treatment. The two study medicines are given after a single dose of obinutuzumab which is the third study medicine. DLBCL is a type of non-Hodgkin lymphoma (NHL). NHL is a cancer of the lymphatic system. It develops when the body makes abnormal B lymphocytes. These lymphocytes are a type of white blood cell that normally help to fight infections. This study is seeking adult participants who: * Have histologically confirmed diagnosis of DLBCL * Have received at least two first lines of treatment for NHL. * Are unable or unwilling to undergo a stem cell transplant or CAR-T cell therapy. Stem cell transplant is a procedure in which a patient receives healthy blood-forming cells to replace their own stem cells that have been destroyed by treatment. A CAR-T therapy is a type of treatment in which a patient's T cells are changed in the laboratory so they will attack cancer cells. Everyone in this study will receive all three medicines at the study site by intravenous (IV) infusion which is given directly into a vein. The two study medicines (maplirpacept \[PF-07901801\] and glofitamab) will be given in 21-day cycles. At Cycle 0, participants will receive a single dose of obinutuzumab pre-treatment followed by two step-up doses of glofitamab. The combination of maplirpacept (PF-07901801) with glofitamab full dose will be administered for the first time at Cycle 1 Day 1. Maplirpacept (PF-07901801) will be given weekly for the first three cycles and then every three weeks. Glofitamab will be given every 3 weeks for approximately 9 months. Thereafter participants will continue to receive maplirpacept alone. Maplirpacept (PF-07901801) will be given at different doses to different participants. Everyone taking part will receive the same fixed doses of glofitamab and obinutuzumab studied in patients with DLBCL. The study will compare the experiences of people receiving different doses of maplirpacept (PF-07901801). This will help to determine what dose is safe and effective when given with the other 2 study medicines. Read Less

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/24/2025

Locations: The University of Kansas Cancer Center ,Investigational Drug Services, Fairway, Kansas +26 locations

The University of Kansas Cancer Center ,Investigational Drug Services, Fairway, Kansas

The University of Kansas Clinical Research Center, Fairway, Kansas

The University of Kansas Hospital, Kansas City, Kansas

University of Kansas Hospital Cambridge North Tower A, Kansas City, Kansas

Allina Health Cancer Institute - Abbott Northwestern Hospital, Minneapolis, Minnesota

Siteman Cancer Center, Saint Louis, Missouri

Barnes-Jewish Hospital Parkview Tower, Saint Louis, Missouri

Barnes-Jewish Hospital, Saint Louis, Missouri

Washington University School of Medicine, Saint Louis, Missouri

Swedish Cancer Institute, Seattle, Washington

Swedish Medical Center, Seattle, Washington

Princess Alexandra Hospital, Brisbane, Queensland

Townsville Hospital and Health Service, Douglas, Queensland

Townsville University Hospital, Townsville, Queensland

St Vincent's Hospital Melbourne, Fitzroy, Victoria

Epworth Freemasons, Melbourne, Victoria

Slade Pharmacy, Richmond, Victoria

Sheba Medical Center, Ramat Gan, Hamerkaz

Rambam Health Care Campus, Haifa, Hatsafon

Sourasky Medical Center, Tel Aviv, Tell Abīb

Hadassah Medical Center, Jerusalem, Yerushalayim

Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Aichi

Shizuoka Cancer Center, Nagaizumi-cho, Shizuoka

National Hospital Organization Kyushu Cancer Center, Fukuoka, Not set

China Medical University Hospital, Taichung, Not set

National Taiwan University Hospital, Taipei, Not set

Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Not set

Conditions: Diffuse Large B-Cell Lymphoma

Learn More ›

A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

NCT05512390

Recruiting

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). Follicular Lymphoma is a slow-growing type of non-Hodgkin lymphoma. Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of ABBV-319 in adult participants in relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL)... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/24/2025

Locations: University of Arizona Cancer Center - Tucson /ID# 247752, Tucson, Arizona +17 locations

Conditions: Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, Follicular Lymphoma

Learn More ›

Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

NCT04002947

Recruiting

Background: Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma. Most people with this cancer can be cured. But those who are not cured have a poor prognosis. Researchers want to add another drug to standard treatment see if it can improve the cure rate. Objective: To see if the drug acalabrutinib given with rituximab and standard combination chemotherapy can improve the cure rate of aggressive B-cell lymphomas such as diffuse large B-cell lymphoma. Eligibility: Pe... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/17/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Diffuse Large B-Cell Lymphoma, DLBCL, NHL, Non-Hodgkin's Lymphoma

Learn More ›

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT06806033

Recruiting

The main goal of this trial is to study the frequency and severity of cytokine release syndrome (CRS) in participants with diffuse large B-cell lymphoma (DLBCL) who are using a combination of glofitamab + gemcitabine + oxaliplatin (Glofit-GemOx) followed by glofitamab-only treatment.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/12/2025

Locations: Alaska Oncology & Hematology, LLC, Anchorage, Alaska +18 locations

Conditions: Diffuse Large B-Cell Lymphoma

Learn More ›

Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma

NCT04850495

Recruiting

This phase Ib trial seeks to find out the best dose and possible side effects and/or benefits of zanubrutinib in combination with the R-PolaCHP in treating patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). Zanubrutinib is designed to block a protein called Bruton Tyrosine Kinase in order to stop cancer growth. R-CHOP is the acronym for the combination of five drugs: rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone. It is the most widely used chemoimmunother... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/11/2025

Locations: Cleveland Clinic, Cleveland, Ohio +2 locations

Conditions: Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma

Learn More ›

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

NCT06717347

Recruiting

The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/11/2025

Locations: The University of Arizona Cancer Center - North Campus ( Site 0124), Tucson, Arizona +167 locations

The University of Arizona Cancer Center - North Campus ( Site 0124), Tucson, Arizona

Cancer Blood and Specialty Clinic ( Site 0109), Los Alamitos, California

Cancer Care Specialists of Illinois ( Site 0152), O'Fallon, Illinois

Fort Wayne Medical Oncology and Hematology ( Site 0149), Fort Wayne, Indiana

Cotton O'Neil Cancer Center ( Site 0108), Topeka, Kansas

Truman Medical Center ( Site 0122), Kansas City, Missouri

OptumCare Cancer Care ( Site 0121), Las Vegas, Nevada

Comprehensive Cancer Centers of Nevada ( Site 0113), Las Vegas, Nevada

New York Oncology Hematology, P.C. ( Site 0129), Albany, New York

The University of Tennessee Medical Center ( Site 0142), Knoxville, Tennessee

University of Virginia Cancer Center ( Site 0138), Charlottesville, Virginia

Virginia Cancer Institute ( Site 0148), Richmond, Virginia

Blue Ridge Cancer Care ( Site 0132), Roanoke, Virginia

SSM Health Dean Medical Group ( Site 0140), Madison, Wisconsin

Clinica Adventista Belgrano ( Site 0309), Caba., Buenos Aires

Instituto de Investigaciones Clinicas Mar del Plata ( Site 0306), Mar del Plata, Buenos Aires

Hospital Universitario Austral ( Site 0307), Pilar, Buenos Aires

Hospital Aleman ( Site 0301), Buenos Aites, Caba

Fundacion Estudios Clinicos ( Site 0311), Rosario., Santa Fe

Hospital Italiano de Buenos Aires ( Site 0304), Caba, Not set

Clinica EL Castaño ( Site 0312), San Juan, Not set

AZ Sint-Maarten, Campus Leopoldstraat 2 ( Site 1102), Mechelen, Antwerpen

ASBL CHU Helora - Hôpital de Mons - Site Kennedy ( Site 1103), Mons, Hainaut

CEONC ( Site 0412), Cascavel, Parana

Hospital Erasto Gaertner ( Site 0401), Curitiba, Parana

Liga Norte Riograndense Contra o Cancer ( Site 0407), Natal, Rio Grande Do Norte

CEPEN - Centro de Pesquisa e Ensino em Oncologia de Santa Catarina ( Site 0403), Florianópolis, Santa Catarina

Hope ( Site 0413), Ribeirao Preto, Sao Paulo

Clinica Advanze ( Site 0411), Sao Carlos, Sao Paulo

F. F. R. M. São Jose do Rio Preto ( Site 0404), Sjrp, Sao Paulo

Biocenter ( Site 0510), Concepcion., Biobio

IC La Serena Research ( Site 0504), La Serena, Coquimbo

Oncocentro Valdivia ( Site 0506), Valdivia, Los Rios

Centro de Estudios Clínicos SAGA ( Site 0508), Santiago., Region M. De Santiago

FALP ( Site 0501), Santiago, Region M. De Santiago

Clinica Inmunocel ( Site 0503), Santiago, Region M. De Santiago

Clínica RedSalud Vitacura ( Site 0512), Santiago, Region M. De Santiago

Centro de Investigaciones ( Site 0511), Vina del mar, Valparaiso

Anhui Provincial Cancer Hospital ( Site 3124), Hefei, Anhui

Beijing Cancer Hospital ( Site 3101), Beijing, Beijing

Chongqing Cancer Hospital ( Site 3113), Chongqing, Chongqing

Fujian Provincial Cancer Hospital. ( Site 3119), Fuzhou, Fujian

The First Affiliated Hospital of Xiamen University ( Site 3120), Xiamen, Fujian

Sun Yat-sen University Cancer Center ( Site 3121), Guangzhou, Guangdong

Zhujiang Hospital of Southern Medical University ( Site 3122), Guangzhou, Guangdong

Affiliated Cancer Hospital of Guangxi Medical University ( Site 3123), Nanning, Guangxi

The Affiliated Hospital of Guizhou Medical University ( Site 3112), Guiyang, Guizhou

Hubei Cancer Hospital ( Site 3125), Wuhan, Hubei

Affiliated Hospital of Nantong University ( Site 3117), Nantong, Jiangsu

Jiangxi Cancer Hospital ( Site 3118), Nanchang, Jiangxi

Shandong Cancer Hospital ( Site 3108), Jinan, Shandong

Shanxi Cancer Hospital ( Site 3106), Taiyuan, Shanxi

1st Affil Hosp of Med College of Xi'an Jiaotong University ( Site 3107), XI An, Shanxi

Sichuan Cancer Hospital. ( Site 3111), Chengdu, Sichuan

West China Hospital, Sichuan University ( Site 3110), Chengdu, Sichuan

Institute of Hematology and Blood Diseases Hosp CAMS&PUMC ( Site 3105), Tianjin, Tianjin

Yunnan Province Cancer Hospital ( Site 3109), Kunming, Yunnan

The First Affiliated Hospital, Zhejiang Medical University ( Site 3116), Hangzhou, Zhejiang

Hospital Pablo Tobon Uribe ( Site 0604), Medellin, Antioquia

IMAT S.A.S ( Site 0603), Montería, Cordoba

Hospital Universitario San Ignacio ( Site 0607), Bogota., Distrito Capital De Bogota

Oncologos del Occidente ( Site 0601), Pereira., Risaralda

Fundación Valle del Lili ( Site 0602), Cali, Valle Del Cauca

Aalborg University Hospital ( Site 1302), Aalborg, Nordjylland

CHU Dijon Bourgogne ( Site 1516), Dijon, Cote-d Or

Centre Hospitalier Universitaire de Limoges - Hôpital Dupuytren ( Site 1512), Limoges, Limousin

Centre Hospitalier Régional Metz Thionville - Hôpital de Mercy ( Site 1515), Metz, Moselle

Centre Hospitalier de Dunkerque ( Site 1513), Dunkerque, Nord

Centre Hospitalier de la Cote Basque ( Site 1509), Bayonne, Pyrenees-Atlantiques

HIA Sainte Anne ( Site 1506), Toulon, Var

Centre Hospitalier d'Avignon ( Site 1505), Avignon, Vaucluse

CHD Vendee ( Site 1502), La Roche-sur-Yon, Vendee

Evangelismos General Hospital of Athens ( Site 1602), Athens, Attiki

General Hospital of Athens "Laiko"-Hematology Department ( Site 1603), Athens, Attiki

Attikon University General Hospital of Athens ( Site 1604), Athens, Attiki

University General Hospital of Alexandroupoli ( Site 1601), Alexandroupolis, Evros

CELAN,S.A ( Site 0702), Guatemala., Not set

MEDI-K ( Site 0701), Guatemala, Not set

Cen Integral Onco Gastro y Hemato Onco Guatemala S.A. ( Site 0703), Guatemala, Not set

Princess Margaret Hospital ( Site 3202), Hong Kong, Not set

Queen Mary Hospital ( Site 3201), Hong Kong, Not set

Carmel Hospital ( Site 1903), Haifa, Not set

Hadassah Medical Center ( Site 1901), Jerusalem, Not set

Sourasky Medical Center ( Site 1904), Tel Aviv, Not set

Poria Medical Center ( Site 1902), Tiberias, Not set

IRCCS Crob ( Site 2002), Rionero in Vulture, Potenza

Istituto di Candiolo IRCCS - Fondazione del Piemonte per l'Oncologia ( Site 2010), Candiolo, Torino

AOU delle Marche Ospedali Riuniti di Ancona ( Site 2011), Ancona, Not set

IRCCS Ospedale San Raffaele ( Site 2012), Milano, Not set

IEO Istituto Europeo di Oncologia ( Site 2009), Milano, Not set

Azienda Ospedaliero Universitaria Maggiore della Carità ( Site 2004), Novara, Not set

Az. Osp. Ospedali Riuniti VILLA SOFIA-CERVELLO ( Site 2005), Palermo, Not set

Ospedale Santa Maria delle Croci ( Site 2006), Ravenna, Not set

Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 2003), Roma, Not set

Nagoya University Hospital ( Site 3309), Nagoya, Aichi

National Hospital Organization Shikoku Cancer Center ( Site 3321), Matsuyama, Ehime

Kobe City Medical Center General Hospital ( Site 3318), Kobe, Hyogo

Kanazawa University Hospital ( Site 3308), Kanazawa, Ishikawa

Tokai University Hospital ( Site 3302), Isehara, Kanagawa

Tohoku University Hospital ( Site 3301), Sendai, Miyagi

Kindai University Hospital ( Site 3310), Osakasayama, Osaka

Saitama Medical University Hospital ( Site 3305), Iruma-gun, Saitama

Juntendo University Hospital ( Site 3307), Bunkyo, Tokyo

University of Yamanashi Hospital ( Site 3320), Chuo, Yamanashi

Chiba Cancer Center ( Site 3314), Chiba, Not set

Kyushu University Hospital ( Site 3313), Fukuoka, Not set

Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital ( Site 3322), Hiroshima, Not set

University Hospital,Kyoto Prefectural University of Medicine ( Site 3315), Kyoto, Not set

University of Miyazaki Hospital ( Site 3319), Miyazaki, Not set

Okayama University Hospital ( Site 3311), Okayama, Not set

Osaka Metropolitan University Hospital ( Site 3317), Osaka, Not set

Yamagata University Hospital ( Site 3312), Yamagata, Not set

National Cancer Center- Center for Hemotologic malignancy ( Site 3806), Goyang-si, Kyonggi-do

Pusan National University Hospital ( Site 3804), Busan, Pusan-Kwangyokshi

Chungnam National University Hospital ( Site 3801), Daejeon, Taejon-Kwangyokshi

Severance Hospital, Yonsei University Health System ( Site 3802), Seoul, Not set

Asan Medical Center ( Site 3803), Seoul, Not set

Samsung Medical Center ( Site 3807), Seoul, Not set

St.Mary's H., Youido ( Site 3805), Seoul, Not set

Queen Elizabeth Hospital ( Site 3405), Kota Kinabalu, Sabah

Sarawak General Hospital ( Site 3402), Kuching, Sarawak

Hospital Miri ( Site 3403), Miri, Sarawak

Sunway Medical Centre ( Site 3406), Petaling Jaya, Selangor

Centro de Infusion Superare ( Site 0804), Ciudad de Mexico, Distrito Federal

Health Pharma Professional Research S.A. de C.V. ( Site 0801), Mexico City, Distrito Federal

Grupo Ollin Care ( Site 0806), Pachuca, Hidalgo

Centro de Investigacion Clinica Chapultepec ( Site 0803), Morelia, Michoacan

Centro de Investigacion Clinica de Oaxaca ( Site 0805), Oaxaca, Not set

Meander Medisch Centrum ( Site 2101), Amersfoort, Utrecht

Albert Schweitzer Ziekenhuis ( Site 2103), Dordrecht, Zuid-Holland

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 2201), Warszawa, Mazowieckie

Wojewódzki Szpital Specjalistyczny im. J. Korczaka w Słupsku ( Site 2210), Słupsk, Pomorskie

Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 2208), Gliwice, Slaskie

Pratia Onkologia Katowice ( Site 2204), Katowice, Slaskie

Szpital Kliniczny Ministerstwa Spraw Wewnętrznych i Administracji z Warmińsko-Mazurskim Centrum Onko ( Site 2205), Olsztyn, Warminsko-mazurskie

Unidade Local de Saude de Braga - Hospital de Braga ( Site 2306), Braga, Not set

Instituto Portugues de Oncologia Do Porto Francisco Gentil E.P.E. ( Site 2302), Porto, Not set

BRCR Global - Mayaguez ( Site 1003), Mayaguez, Not set

Auxilio Mutuo Cancer Center ( Site 1001), San Juan, Not set

Institutul Oncologic Cluj ( Site 2404), Cluj-Napoca, Cluj

Spital Judetean Sibiu ( Site 2405), Sibiu, Not set

National University Hospital ( Site 3702), Singapore, Central Singapore

National Cancer Centre Singapore ( Site 3701), Singapore, Central Singapore

Haemalife ( Site 2501), Cape Town, Western Cape

Hospital Universitario Virgen Macarena ( Site 2608), Sevilla, Andalucia

ICO L Hospitalet ( Site 2601), Hospitalet de Llobregat, Barcelona

H. Insular de Gran Canaria ( Site 2606), Las Palmas de Gran Canaria, Las Palmas

Hospital General Universitario Dr. Balmis ( Site 2604), Alicante, Valenciana, Comunitat

Hospital del Mar ( Site 2610), Barcelona, Not set

Hospital Universitario La Paz ( Site 2611), Madrid, Not set

Hospital Virgen de la Victoria ( Site 2609), Malaga, Not set

Hospital Universitario Miguel Servet ( Site 2607), Zaragoza, Not set

Ospedale Regionale Bellinzona e Valli ( Site 2701), Bellinzona, Ticino

Chang Gung Memorial Hospital - Linkou Branch ( Site 3903), Taoyuan City, Taoyuan

Chang Gung Memorial Hospital at Kaohsiung ( Site 3905), Kaohsiung, Not set

National Cheng Kung University Hospital ( Site 3902), Tainan, Not set

National Taiwan University Hospital ( Site 3901), Taipei, Not set

Mackay Memorial Hospital ( Site 3908), Taipei, Not set

Tri-Service General Hospital ( Site 3906), Taipei, Not set

Maharaj Nakorn Chiang Mai Hospital ( Site 4002), Muang, Chiang Mai

Chulalongkorn University ( Site 4003), Pathumwan, Krung Thep Maha Nakhon

MNPE ClinCenter of Oncology,Hematology,Transplantology and Palliative Care of CherkasyRegCouncil ( Site 2904), Cherkasy, Cherkaska Oblast

Communal non-profit enterprise "Regional clinical hospital of Ivano-Frankivsk Regional Council" ( Site 2906), Ivano-Frankivsk, Ivano-Frankivska Oblast

Khmelnytskyi Regional Hospital ( Site 2907), Khmelnytskiy, Khmelnytska Oblast

Institute of Blood Pathology and Transfusion Medicine AMS Ukraine ( Site 2903), Lviv, Lvivska Oblast

SNPE National Cancer Institute ( Site 2902), Kyiv, Not set

Universal Clinic Oberig ( Site 2908), Kyiv, Not set

Public Non-Profit Enterprise Kyiv City Clinical Hospital #9 under the Executive Body of Kyiv City Co ( Site 2905), Kyiv, Not set

Conditions: Diffuse Large B-Cell Lymphoma

Learn More ›

Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma

NCT05455697

Recruiting

This phase I/II trial tests the safety of tafasitamab, retifanlimab, and rituximab (TRR) as a prephase treatment and in combination with standard therapy consisting off cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or polatuzumab vedotin, cyclophosphamide, doxorubicin, and prednisone (PolaCHP) in patients with untreated diffuse large B-cell lymphoma. Tafasitamab, retifanlimab, and rituximab are monoclonal antibodies. Tafasitamab binds to a protein called CD19, which is found... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/09/2025

Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington

Conditions: Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma

Learn More ›

A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers.

NCT06870487

Recruiting

The purpose of this study is to learn about the effects of a new study medicine called PF-08046032, when taken alone and when taken with another medicine called sasanlimab, for the treatment of advanced cancers. The effects are studied in adult participants with certain types of lymphomas or solid tumors that are advanced or metastatic (spread to other parts of the body). The study has three parts: * Part A will test PF-08046032 alone at increasing dose levels in participants with certain lymp... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/09/2025

Locations: The University of Texas MD Anderson Cancer Center, Houston, Texas +5 locations

Conditions: Peripheral T Cell Lymphoma, Diffuse Large B-cell Lymphoma, Classical Hodgkin Lymphoma, Head and Neck Squamous Cell Carcinoma, Melanoma, Non-Small Cell Lung Cancer

Learn More ›

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

NCT06395103

Recruiting

Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma (DLBCL)/Burkitt lymphoma, or neuroblastoma and in pediatric and young adult participants with Ewing sarcoma.

Gender:

ALL

Ages:

Between 6 months and 25 years

Trial Updated:

06/06/2025

Locations: Children's Hospital Los Angeles ( Site 1006), Los Angeles, California +53 locations

Children's Hospital Los Angeles ( Site 1006), Los Angeles, California

Children's Hospital Colorado-Center for Cancer and Blood Disorders ( Site 1016), Aurora, Colorado

Yale-New Haven Hospital ( Site 1012), New Haven, Connecticut

Johns Hopkins All Children's Hospital ( Site 1025), Saint Petersburg, Florida

University of Iowa-Holden Comprehensive Cancer Center ( Site 1017), Iowa City, Iowa

Dana-Farber Cancer Institute ( Site 1013), Boston, Massachusetts

Corewell Health ( Site 1001), Grand Rapids, Michigan

Children's Mercy Hospital ( Site 1024), Kansas City, Missouri

Rutgers Cancer Institute of New Jersey ( Site 1008), New Brunswick, New Jersey

New York Medical College ( Site 1023), Valhalla, New York

Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 1003), Fargo, North Dakota

Oregon Health and Science University ( Site 1004), Portland, Oregon

Children's Hospital of Philadelphia (CHOP) ( Site 1021), Philadelphia, Pennsylvania

Sanford Children's Hospital-Sanford Children's Specialty Clinic ( Site 1015), Sioux Falls, South Dakota

University of Texas MD Anderson Cancer Center ( Site 1007), Houston, Texas

Intermountain - Primary Children's Hospital ( Site 1014), Salt Lake City, Utah

Sydney Children's Hospital-Kids Cancer Centre ( Site 1997), Randwick, New South Wales

Queensland Children's Hospital-Oncology & Haematology ( Site 1996), Brisbane, Queensland

UZ Gent ( Site 1428), Gent, Oost-Vlaanderen

Hospital Erasto Gaertner-CEPEP - Pesquisa Clínica ( Site 1268), Curitiba, Parana

Hospital de Clinicas de Porto Alegre ( Site 1265), Porto Alegre, Rio Grande Do Sul

Fundação Pio XII - Hospital de Câncer de Barretos ( Site 1264), Barretos, Sao Paulo

Fundação Faculdade Regional de Medicina de São José do Rio Preto-Centro Integrado de Pesquisa ( Site 1267), São José do Rio Preto, Sao Paulo

Hospital Carlos Van Buren ( Site 1880), Valparaíso, Valparaiso

Hospital Pablo Tobon Uribe ( Site 1923), Medellin, Antioquia

Clinica de la Costa S.A.S.-Clinical Research Oncology & Hematology -Pediatric ( Site 1924), Barranquilla, Atlantico

IMAT S.A.S ( Site 1921), Monteria, Cordoba

Rigshospitalet-Department of paediatrics and adolescent medicine, Section of Paed haem-onc ( Site 1467), Copenhagen, Hovedstaden

CHU de Bordeaux. Hopital Pellegrin ( Site 1105), Bordeaux, Aquitaine

Gustave Roussy ( Site 1103), Villejuif, Ile-de-France

Centre Hospitalier Universitaire de Nantes - Hôpital Femme-Enfant-Adolescent Chu De Nantes ( Site 1104), Nantes, Pays-de-la-Loire

CENTRE LEON BERARD-IHOPE (pediatrric oncology) ( Site 1100), Lyon, Rhone-Alpes

Universitätsklinikum Münster - Albert Schweitzer Campus-Pädiatrische Hämatologie und Onkologie ( Site 1141), Münster, Nordrhein-Westfalen

Aghia Sophia Children's Hospital-First Department of Pediatrics, National and Kapodistrian Universi ( Site 1797), Athens, Attiki

Semmelweis Egyetem ( Site 1838), Budapest, Not set

Rambam Health Care Campus-Pediatric Hemato-Oncology ( Site 1674), Haifa, Not set

Sheba Medical Center ( Site 1675), Ramat Gan, Not set

Fondazione IRCCS Istituto Nazionale dei Tumori-Pediatric Oncology ( Site 1552), Milan, Lombardia

Ospedale Pediatrico Bambino Gesù IRCCS-Dipartimento di Onco-Ematologia e Terapia Cellulare e Genica ( Site 1553), Rome, Roma

Seoul National University Hospital-Pediatrics ( Site 1972), Seoul, Not set

Asan Medical Center-Pediatrics - Pedicatric Oncology ( Site 1973), Seoul, Not set

Prinses Maxima Centrum voor Kinderoncologie ( Site 1510), Utrecht, Not set

Hospital Sant Joan de Déu-Pediatric Oncology Department ( Site 1717), Esplugas De Llobregat, Barcelona

Hospital Infantil Universitario Niño Jesús-Servicio de Onco-Hematología Pediátrica ( Site 1715), Madrid, Madrid, Comunidad De

Hospital Universitari Vall d'Hebron-Servei de Hematologia i Oncologia Pediatrica ( Site 1716), Barcelona, Not set

Prövningsenhet barn, Sahlgrenska Universitetssjukhuset ( Site 1634), Gothenburg, Vastra Gotalands Lan

National Taiwan University Hospital ( Site 1983), Taipei, Not set

Hacettepe Universite Hastaneleri ( Site 1961), Ankara, Not set

Ankara Bilkent Şehir Hastanesi ( Site 1962), Ankara, Not set

Ege Universitesi Hastanesi ( Site 1963), İzmir, Not set

Royal Victoria Infirmary-Great North Children's Hospital ( Site 1348), Newcastle upon Tyne, England

University College London Hospital ( Site 1350), London, London, City Of

Royal Marsden Hospital (Sutton)-Drug Development Unit ( Site 1347), Sutton., Surrey

University Hospital of Wales ( Site 1346), Cardiff, Not set

Conditions: B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma, Ewing Sarcoma

Learn More ›

1 - 12 of 34